This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit May 14, 2014

Home   About   Membership   Awards   Knowledge Center   Divisions   Advocacy   Career Center        


 


ASPET NEWS


ASPET Seeks Education Manager
ASPET
ASPET is hiring! We are currently seeking to hire a highly-motivated education manager who can successfully create, implement, and promote ASPET's educational programs and serve as staff liaison to support all of our education-related activities. This position is based out of our offices in Bethesda, MD.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Goodman and Gilman Fund Is Now Fully Endowed
ASPET
We are pleased to announce that we have met our endowment goal of $60,000 towards the Goodman and Gilman award and thank all our donors who made it possible for us to reach our target.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Support the John J. Abel Award in Pharmacology by donating to the John J. Abel Award Endowment Fund
ASPET
The Abel Award recognizes young scientists who are doing fundamental research in pharmacology and experimental therapeutics. Help us reach our goal of raising $200K by taking the time now to make your tax-deductible donation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
CLICK HERE


Early Career Reviewer Program
ASPET
Thinking about becoming an Early Career Reviewer? The NIH Center for Scientific Review (CSR) Early Career Reviewer (ECR) program was developed to train qualified scientists without prior CSR review experience to become effective reviewers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Joint APS/ASPET T32 Grant Program Update
ASPET
Dr. Richard Okita, Program Director at NIGMS/NIH presented the Institutional Research Grants (T32) Announcement at Experimental Biology 2014. The primary objective of the T32 program is to ensure that a diverse pool of highly trained scientists is available to address our nation’s biomedical, behavioral, and clinical research needs.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
VIEW PRESENTATION


Presentation on Career Paths for Medical Writing
ASPET
During the ASPET Diversity and Mentoring Breakfast at EB 2014, Dr. Victoria Love, Section Manager for Documentation and Archiving at Allergan, gave a very informative presentation on career paths for medical writing and the scope of work encompassed by the field.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
VIEW PRESENTATION


FASEB Releases New Bioscience Article on Epigenetics
ASPET
FASEB released the latest publication in the Horizons in Bioscience series titled "Epigenetics: Looking Beyond Our DNA." The article describes the emerging field of epigenetics and its contributions toward treating and preventing disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SCIENCE POLICY NEWS


Legislative Update: House Labor-HHS Appropriations Subcommittee Receives $1 billion Cut in FY 2015
ASPET
The House Appropriations Committee has allocated their spending levels for each of the 12 subcommittees. These allocations are called the 302(b) sub-allocations and limit the total spending for each of the 12 appropriations bills in the House (and Senate).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FASEB State Factsheets Highlight FY 2013 NIH Funding
ASPET
FASEB released updated FY 2013 state factsheets that show how funding from the NIH benefits each state.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FDA's China Director Discusses Agency Efforts on Product Safety
ASPET
Christopher Hickey, FDA's Country Director for China discusses the agency's efforts to assure product safety in imports from China.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


ASPET ANNUAL MEETING AT EB 2014 NEWS


Thank you for Attending EB 2014
ASPET
With over 13,000 attendees, the ASPET Annual Meeting at EB 2014 was a great success. EB 2014 abstracts are available online in The FASEB Journal at http://www.fasebj.org/content/28/1_Supplement.toc. We will be posting pictures from the meeting online and in The Pharmacologist soon. Also be sure to look out for the Post-EB 2014 survey to give us your feedback. Our next annual meeting will be held in Boston from March 28–April 1 next year — be sure to save the date!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


NEWS FROM THE FIELD


Preliminary results show improvement in MS symptoms
National Institutes of Health
Combining the estrogen hormone estriol with Copaxone, a drug indicated for the treatment of patients with relapsing forms of multiple sclerosis, may improve symptoms in patients with the disorder, according to preliminary results from a clinical study of 158 patients with relapsing remitting multiple sclerosis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


What really drives drug development inefficiencies — Part I
By Mike Wokasch
There are currently more than 5,000 potential new drug treatments in clinical trials. Yet every year the U.S. Food and Drug Administration approves fewer than 50 new drugs, and many of these approvals include new indications for previously-approved drugs. The dismal success rate is often held up as proof that drug development is difficult and high risk. And the industry and investors continue to believe that more shots on goal means a higher probability of something useful making it through the drug development and regulatory gauntlet. OK, so clinical drug development is difficult, but is it unnecessarily inefficient?
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


New cell structure discovery could aid drug development
Drug Discovery & Development
The structure of sodium channels — which play an essential role in the functioning of heart and nerve cells — are different than previously believed. Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions. Sodium channels are implicated in many serious conditions such as heart disease, epilepsy and pain, making them an important potential target for drug therapies
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



ASPET News Brief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Caitlin Harrison, MultiView Content Editor, 469.420.2657  
Contact MultiView


Prateeksha Nagar, ASPET Contact, 301.634.7916
Contact ASPET


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the ASPET News Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!

Recent issues

April 16, 2014
April 2, 2014
March 19, 2014
March 5, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063